A Phase II Study of Pre-Operative Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, and Trastuzumab in Patients With Operable Breast Cancer Over-expressing Her2-neu

Inclusion Criteria:

- Dx of clinical T1c-T3, N0-1, M0 breast cancer

- Interval between diagnosis and consent of <- 62 days

- Life expectancy of 10 years

- LVEF by MUGA >= lower limit of normal for the testing facility

- Negative serum pregnancy test

- Adequate bone marrow, renal, liver function

- Negative bone scan

- HRT discontinued before study entry

- Adequate contraceptive methods

Exclusion Criteria:

- Male breast cancer

- Less than 21 years of age

- Ulceration, infiltration of the skin, complete fixation or severe skin edema

- N3 disease in which nodes are matted and fixed

- Suspicious palpable supraclavicular nodes

- CT evidence of malignant internal mammary nodes

- Pregnancy or breast feeding at time of study entry

- Prior therapy for breast cancer

- Prior anthracycline for any malignancy

- Prior breast malignancy of the contralateral breast

- Prior non-breast malignancy within 5 years

- Non-malignant disease that would preclude follow up

- MI within 6 months, NYHA Class II or greater heart failure

- Psychiatric disorders or conditions that would preclude provision of informed consent